The global optogenetics actuators and sensors market size was valued at $ 546 million in 2021 and is expected to reach $644.8 million by 2030 expanding at a CAGR of 2.1% from 2022 to 2030.
Optogenetics is a technique for controlling neural activity using optically triggered proteins. It is a new advancement in neuroscience that offers therapeutic possibilities for incurable disorders such as retinal diseases, Parkinson's disease, and Alzheimer's disease. Optogenetic methods allow for highly precise spatial, temporal, and neurochemical activation or inhibition of neurons. A gene that codes for a light-sensitive protein is extracted from algal species using this approach. The neural signal is transmitted when a flashing light is shone on a specific brain cell. This method may be used to regulate neuron mobility and gain a better understanding of how brain cells work at the molecular level.
Advancements in optogenetics have been on a rise. The method makes it possible to see and visualize various parts of the brain as well as the functions that are responsible for memory, emotion, and attention. This helps to avoid the development of neurological and psychological problems that are passed down via families. In the medical field, injectable devices that place nerves under wireless control are now being developed using a variety of ultrathin and flexible microchips.
|Market Size||$644.8 million|
|Fastest Growing Market||Asia Pacific|
|Largest Market||North America|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
The factors that are boosting the growth of the optogenetics actuators and sensors market include an increase in the prevalence of retinal diseases and neurological disorders among populations all over the world, extensive development and research in the field of optogenetics, and initiatives taken by the government in the form of financial support.
The increasing use of this sophisticated method contributes to a better understanding of the biochemical and physiological pathway that is responsible for the cause of a specific disease, as well as the identification of an accurate treatment option for that disease. This is accomplished by flashing blue light on particular neural cells.
Technological advancements in the field of neuroscience also help to accelerate the growth of the optogenetics actuators and sensors market. The optogenetics actuators and sensors market is being influenced by the growing popularity of optogenetics as a result of its properties, such as the prevention of the development of inherited neurological and psychiatric disorders and the employment of numerous ultrathin and flexible microchips as injectable devices that put nerves under wireless control.
Additionally, an increasing number of research and development activities to improve the treatment for specific diseases, an increase in the population of elderly people, a surge in investment by both the private and public sectors, and an increase in the amount spent on healthcare all have a positive impact on the market for optogenetics actuators and sensors.
It is anticipated that the rising cost of innovation would have an effect on market development. Alongside moral guidelines for the care of animals, it is anticipated that this would slow the expansion of the worldwide market for optogenetic actuators and sensors.
The United States of America led the rest of the world in terms of market share, which North America generally held. The dominance of this area may be ascribed to a number of different aspects, some of which include the local presence of market participants, ongoing research and development, technological breakthroughs, and a well-established healthcare framework in the region.
In addition, financing from both public and private institutions is a significant component that is propelling the industry in North America. Research into Parkinson's disease received a recent investment of around 107 million US dollars from the National Institute of Neurological Disorders and Strokes (NINDS), which is a component of the National Institutes of Health (NIH). In addition, the organization is launching a variety of projects, such as the Parkinson's Disease Biomarkers Programs (PDBP), research and discovery-oriented effort, with the goal of lowering the prevalence of neurodegenerative and mental diseases in the area.
It is anticipated that Asia Pacific would be the category with the highest growth rate due to the emergence of new economies in the area as well as a rise in the amount spent on R&D. Additionally, it is envisaged that the creation of money would be fueled through cooperation across companies. The participation of the area in a variety of conferences and seminars is another factor that is expected to boost the market growth.
Investigations on a much more extensive scale are helping to contribute to technical advancements in the region. For example, research projects like those being carried out by the RIKEN-MIT Centre for Neural Circuit Genetics and the Japan Science and Technology Agency in conjunction with other international organizations are anticipated to play a significant role in the expansion of the region in the years to come.
The optogenetics actuators and sensors market is segmented into the following categories: Product, Disease type and region.
The market is classified into Actuators (Channel rhodopsin, Halo rhodopsin, Archaerhodopsin) And Sensors (Genetically Encoded Calcium Indicators, Voltage-Sensitive Fluorescent Proteins, pH Sensors) based on Product. It is anticipated that the sector of this market that will have the most growth would be sensors. It is projected that major investments by industrial organizations would promote the growth of this market sector. These expenditures will go toward the development of genetically encoded calcium indicators, voltage-sensitive fluorescent proteins, and pH sensors. Voltage-sensitive fluorescent protein-based sensors have been created by researchers, and these sensors are able to deliver crucial voltage data. In addition, a wide range of active research projects aimed at developing rapid fluorescent protein voltage sensors is being carried out. Scientists are now working on the development of such sensors by perfecting the interactions known as Foster Resonance Energy Transfer (FRET), which may be useful in the monitoring of neural processes in vivo. It is anticipated that the completion of this research, which is supported financially by both private and governmental entities, will contribute to an increase in market share in the years to come.
Based on the kind of disease, the market is divided into categories for retinal disorders, Parkinson's disease, anxiety and depression, autism, and schizophrenia. The greatest market share belongs to retinal disorders, whose rise may be explained by an increase in cases of retinitis pigmentosa, glaucoma, and diabetes-related retinal illnesses. In the market for optogenetics actuators and sensors, the highest proportion is accounted for by the treatment of retinal illnesses. A primary driver that is driving the segment is the rising prevalence of retinal illnesses that are associated with diabetes, such as retinitis pigmentosa, glaucoma, and others. Glaucoma affects the eyes of more than 2.7 million individuals in the United States at the current time, and it is projected that this figure will rise to 4.2 million by the year 2030, according to statistics provided by the National Institute of Health (NIH). More than 7.7 million persons age 40 and older are living with diabetic retinopathy at the moment, and this number is predicted to rise to 11 million by the year 2030.
The area of the market known as neurological diseases is being propelled forward by the rising prevalence of neurological and mental conditions including Parkinson's disease, depression, and schizophrenia. To lessen the impact that brain illnesses have on society as a whole, the National Institutes of Health (NIH) supports a variety of research initiatives and treatment programs that focus on neurological and mental health issues. In addition, a number of different organizations are concentrating their efforts on investments, developments, and fellowship awards in order to promote projects in this area.
Researchers at the Gladstone Institutes have made a remarkable breakthrough in the treatment of Parkinson's disease by identifying a brain circuit that helps govern walking and find new targets. While recording the neuronal processes in brains, researchers used optogenetics to activate "go" and "stop" pathways responsible for triggering locomotion. These pathways are responsible for triggering locomotion. According to the findings of the study, just a particular group of neurons located in the brainstem are required and sufficient to kickstart movement.
Based on Region, The global optogenetics actuators and sensors market is classified into North America, Europe, Asia Pacific and Latin America and Middle East.
Circuit Therapeutics, Inc. worked together on a project with the pharmaceutical business Boehringer Ingelheim, which is situated in Germany. Circuits Therapeutics, Inc. shall, in accordance with the terms of the agreement, deliver its optogenetic technology platform for the purpose of identifying and characterizing novel therapeutic targets derived from brain circuits. The mission of the firm is to create innovative treatments for the treatment of mental diseases. It is anticipated that this connection will propel technical advancements in the relevant industry.
LabCentral is a research resource and lab space supplier for companies and individual entrepreneurs located in the United States. Merck KGaA has announced that they would be collaborating with LabCentral. It is anticipated that the company would provide sponsorship for new businesses at LabCentral and eventually speed up research in the field of life science. In the next years, it is anticipated that these types of collaborations will encourage an increase in the study and development of innovative medicines for neurological illnesses.